Answers are grounded in this paper and cite their sources.
As noted by El-Orbany et al.,1 residual neuromuscular blockade (RNMB) continues to be an anesthetic complication that is frequently observed in contemporary clinical practices. In a meta-analysis of data from 24 clinical trials (3375 patients), the pooled incidence of RNMB (train-of-4 <0.9) in patients receiving intermediate-acting muscle relaxants was 41%.2 The authors concluded that there is a “continued high incidence of RNMB reported from multiple academic centers” and that “large numbers of practitioners still fail to monitor neuromuscular function and fail to administer antagonist when appropriate.”2 In addition, evidence is accumulating that patients with RNMB in the postanesthesia care unit (PACU) are at increased risk for a number of adverse events, including respiratory complications,3 unpleasant symptoms of muscle weakness,4 and prolonged PACU length of stay.5 El-Orbany et al.1 urge that objective monitoring devices should be routinely applied in clinical practice to determine when neuromuscular function has recovered and tracheal extubation can be safely performed.1 This is not the first call for objective quantitative monitors in all operating rooms. In an important editorial in 2003, Eriksson6 stated that “it is time to introduce objective neuromuscular monitoring in all operating rooms” and that “objective neuromuscular monitoring should consequently be used whenever a non-depolarizing neuromuscular blocking agent is administered.” Furthermore, a recent evidence-based review concluded that “ideally, neuromuscular function should be monitored objectively (quantitatively) in all patients receiving neuromuscular blocking drugs.”7 The introduction of quantitative monitors into clinical practice can significantly reduce the risk of RNMB. Randomized trials have demonstrated that the incidence of residual paresis can be decreased by >75% if acceleromyography monitoring is used.7 In a large clinical practice, the increased use of quantitative monitoring (from 2% to 60%) and anticholinesterase reversal (from 6% to 42%) over time was associated with a reduction in the incidence of RNMB (train-of-4 <0.9) from 62% to 3%.8 Despite evidence that quantitative monitoring reduces the number of patients with RNMB and associated complications in the PACU, only 22.7% of anesthesia departments in the United States have such monitoring available.9 Why evidence-based practices demonstrating a reduced risk of postoperative RNMB have not been adopted by anesthesiologists around the world is uncertain. What seems certain however is that patients will continue to be at risk for adverse events associated with incomplete neuromuscular recovery until national and international anesthesia societies actively promote changes in current practices related to dosing, monitoring, and reversal of muscle relaxants. Conflicts of Interest: Glenn S. Murphy consulted for Merck and reported a conflict of interest with Merck Advisory Board. Glenn S. Murphy, MD Joseph W. Szokol, MD Steven B. Greenberg, MD Torin Shear, MD Department of Anesthesiology NorthShore University HealthSystem Evanston, Illinois [email protected] Michael J. Avram, PhD Department of Anesthesiology Northwestern University Feinberg School of Medicine Chicago, Illinois
No takes yet. Share an insight, caveat, or question.
Murphy et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: